Disparities in receiving disease‐directed therapy, allogeneic stem cell transplantation in non‐Hispanic Black patients with TP53‐mutated acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34604
Abstract: Although the clinical outcomes of patients with TP53‐mutated acute myeloid leukemia (AML) are dismal, subsets of patients eligible for curative‐intent therapies may fare better. Because racial disparities are known to affect outcome in hematologic malignancies,… read more here.
Keywords: mutated acute; myeloid leukemia; patients tp53; acute myeloid ... See more keywords
Hedgehog signaling negatively co-regulates BH3-only protein Noxa and TAp73 in TP53-mutated cells.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer letters"
DOI: 10.1016/j.canlet.2018.04.025
Abstract: In the present study, we show that pharmacological repression by the Hedgehog (Hh) pathway inhibitor (HPI) GANT61 induces expression of the proapoptotic protein Noxa in TP53-mutated embryonal pediatric tumor cells driven by Hh signaling (i.e.… read more here.
Keywords: protein; protein noxa; tp53 mutated; noxa tap73 ... See more keywords
Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen
Sign Up to like & getrecommendations! Published in 2022 at "Leukemia Research Reports"
DOI: 10.1016/j.lrr.2021.100286
Abstract: Myeloid sarcoma (MS) is a rare extramedullary blast proliferation of immature cells of myeloid origin. It is commonly associated with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or myeloproliferative neoplasm (MPN), and may precede, coincide… read more here.
Keywords: tp53 mutated; myeloproliferative neoplasm; decitabine venetoclax; myeloid sarcoma ... See more keywords
Arsenic Trioxide exerts cytotoxic and radiosensitizing effects in pediatric Medulloblastoma cell lines of SHH Subgroup
Sign Up to like & getrecommendations! Published in 2020 at "Scientific Reports"
DOI: 10.1038/s41598-020-63808-9
Abstract: We evaluated the potential effects of ATO in different pediatric SHH-MB cell lines (ONS-76: TP53 -wild type; DAOY and UW402: TP53 -mutated). MB cell lines molecular subgroup was confirmed and TP53 mutations were validated. Cell… read more here.
Keywords: subgroup; shh cell; tp53 mutated; cell lines ... See more keywords
Clinical outcomes and characteristics of patients with TP53-mutated myelodysplastic syndromes.
Sign Up to like & getrecommendations! Published in 2023 at "Hematology"
DOI: 10.1080/16078454.2023.2181773
Abstract: OBJECTIVE To explore the clinical outcomes and characteristics of TP53-mutated primary myelodysplastic syndromes (MDS). METHODS A total of 74 de novo primary MDS patients who were diagnosed and treated in the Department of Hematology of… read more here.
Keywords: clinical outcomes; group; hematology; tp53mut group ... See more keywords
Precision medicine for TP53-mutated acute myeloid leukemia
Sign Up to like & getrecommendations! Published in 2019 at "Expert Review of Precision Medicine and Drug Development"
DOI: 10.1080/23808993.2019.1644164
Abstract: ABSTRACT Introduction: TP53 mutations in acute myeloid leukemia (AML) are associated with poor response to standard chemotherapy and high rates of relapse, even after allogeneic stem cell transplantation. The mutated p53 protein is likely to… read more here.
Keywords: medicine; tp53 mutated; myeloid leukemia; acute myeloid ... See more keywords
PIK3CA somatic mutations as potential biomarker for immunotherapy in elder or TP53 mutated gastric cancer patients
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Genetics"
DOI: 10.1111/cge.14260
Abstract: Immune checkpoint inhibitors (ICIs) improve overall survival in patients with advanced gastric cancer (GC). However, the molecular characterization of GC in ICIs responders is unclear. A total of 288 advanced GC patients were included in… read more here.
Keywords: tp53; gastric cancer; somatic mutations; tp53 mutated ... See more keywords
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Discovery"
DOI: 10.1158/2159-8290.cd-22-0332
Abstract: Abstract TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) form a distinct group of myeloid disorders with dismal outcomes. TP53-mutated MDS and AML have lower response rates to either induction chemotherapy, hypomethylating agent–based regimens,… read more here.
Keywords: myeloid; tp53 mutated; myelodysplastic syndrome; biology ... See more keywords
Droplet Digital PCR Monitoring of TP53 Mutated Circulating Tumor DNA Levels in Lymphoma Patients
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-113825
Abstract: INTRODUCTION: Circulating tumor DNA (ctDNA), a portion of circulating cell-free DNA (cfDNA), is released from tumor cells into the circulatory system, which contains mutations corresponding to the patient's tumour alleles. Detection of ctDNA may noninvasively… read more here.
Keywords: ctdna; tp53 mutated; dna; lymphoma patients ... See more keywords
Molecular Characteristics That Predict Response to Azacitidine Therapy
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-129420
Abstract: Background DNA hypomethylating agents (HMAs), including azacytidine (AZA) and decitabine, have been established as key drugs for higher-risk myelodysplastic syndromes (MDS). Recently, a marked efficacy of decitabine has been reported in TP53-mutated myeloid malignancies, although… read more here.
Keywords: response; tp53 mutated; remission; aza ... See more keywords
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2021014956
Abstract: Abstract There is a growing body of evidence that therapy-related myeloid neoplasms (t-MNs) with driver gene mutations arise in the background of clonal hematopoiesis (CH) under the positive selective pressure of chemo- and radiation therapies.… read more here.
Keywords: related myeloid; myeloid neoplasms; therapy related; treatment ... See more keywords